Regulus

RGLS NASDAQ
0.9698
-0.0302
-3.02%
Closed 16:00 06/14 EDT
Open
1.000
Prev Close
1.000
High
1.050
Low
0.9500
Volume
201.28K
Avg Vol (3M)
184.63K
52 Week High
8.99
52 Week Low
0.8000
% Turnover
0.98%
Market Cap
19.93M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Regulus RGLS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
MORE >

Recently

Name
Price
%Change